Business Context and Reporting Period
Company: CRISPR Therapeutics AG
Filing Type: Form 8-K (Current Report)
Date of Report: September 17, 2018
Event: Entry into a Material Definitive Agreement with ViaCyte, Inc. to develop allogeneic cell therapies for diabetes (Type 1, Type 2, and insulin-dependent) using gene-edited human stem cells.
Key Financial Metrics and Transaction Terms
This filing details a strategic collaboration rather than periodic financial results. Key financial terms of the agreement include:
- Consideration to ViaCyte: Approximately $15.0 million in CRISPR common shares (issued in two tranches) plus $10,000 in cash.
- Share Issuance Structure:
- First Tranche: $7.5 million in shares + $5,000 cash (issued 5 business days after agreement).
- Second Tranche: Remaining value to reach $15.0 million net proceeds + $5,000 cash (issued after Q3 2018 10-Q filing).
- Price Adjustment: If net proceeds from share sales differ from $15.0 million, a cash payment is made to equalize the value.
- Future Financing Option: If ViaCyte fails to raise $25.0 million in preferred stock financing by January 15, 2019, it may exercise an option for a $10.0 million convertible promissory note from CRISPR.
- Cost Sharing (Post-POC): If a Proof of Concept (POC) is established, development costs are split 60% CRISPR / 40% ViaCyte until first commercial sale; profits are shared equally thereafter.
- Termination Milestones: If the agreement is terminated under specific conditions, the continuing party may owe milestone payments up to $25.0 million and single-digit royalties.
Note: The filing does not provide current revenue, profit, cash flow, or debt metrics for CRISPR Therapeutics AG.
Material Changes and Strategic Outlook
Strategic Shift: The company has expanded its research pipeline into diabetes treatment through a joint research plan with ViaCyte. The research term lasts until a POC is established or five years from the agreement date, subject to extensions.
Governance: A Joint Research Committee (JRC) with three representatives from each party will oversee activities, requiring consensus for decisions.
Non-Competition: During the research term, neither party can conduct activities in the defined field (allogeneic cell therapy for diabetes) with third parties. Acquired "Distracting Products" must be divested, integrated, or development ceased.
Risks and Contingencies:
- Financing Risk: CRISPR faces a potential $10.0 million contingent liability if ViaCyte cannot secure external funding by January 2019.
- Commercialization Uncertainty: A separate Commercialization Agreement must be negotiated if a POC is reached; failure to agree triggers dispute resolution.
- Termination Triggers: The agreement can be terminated for convenience (with restrictions), material breach, insolvency, or patent challenges.
Investor Verification Checklist
- Verify the exact number of shares issued in the first tranche based on the closing price on the issuance date.
- Monitor ViaCyte's financing progress by January 15, 2019, to assess the likelihood of the $10.0 million convertible note obligation.
- Review the upcoming Form 10-Q for the three months ended September 30, 2018, for the issuance of the second tranche of shares.
- Track the progress of the Joint Research Committee and the timeline for establishing a Proof of Concept (POC).
- Assess the impact of the non-competition clause on CRISPR's ability to partner with other entities in the diabetes field.